摘要
虽然近年来单克隆抗体、小分子靶向药物和免疫治疗等新药的应用明显提高了恶性淋巴瘤患者的近期疗效和长期生存,但造血干细胞移植在恶性淋巴瘤的整体治疗中仍然具有重要的地位。为提高临床医师对造血干细胞移植在恶性淋巴瘤治疗中作用和地位的认识,并规范其临床应用,以提高恶性淋巴瘤的整体治疗水平,中国抗癌协会血液肿瘤专业委员会联合中华医学会血液学分会白血病淋巴瘤学组和中国临床肿瘤学会抗淋巴瘤联盟的相关专家,制订了《造血干细胞移植治疗淋巴瘤中国专家共识(2018版)》。对造血干细胞移植治疗淋巴瘤的适应证、移植方式、造血干细胞动员和采集、移植预处理、移植前后治疗以及随访和监测等主要内容进行了详细阐述,以供临床医师参考。
Although addition of novel monoclonal antibodies, targeted therapies, and immune therapies have remarkably improved both response and long-term survival of malignant lymphoma, hematopoietic stem cell transplantation ( HSCT) remains an important therapeutic option for lymphomas. In order to improve the understanding of the roles of hematopoietic stem cell transplantation for malignant lymphoma and further standardize the clinical application, the Chinese experts from the Hematology Oncology Committee of China Anti-Cancer Association, the Leukemia&Lymphoma Group of the Society of Hematology at Chinese Medical Association and the Chinese Union of Lymphoma Research of the Chinese Society of Clinical Oncology, have analyzed the related research data and developed the Chinese expert consensus on hematopoietic stem cell transplantation for malignant lymphoma ( 2018 ). In this consensus, we have systematically expounded on the indication, type of transplant, mobilization and collection of hematopoietic stem cells, conditioning regimen, pre-or post transplant therapies and follow-up of HSCT for malignant lymphoma, in order to provide reference for clinicians.
作者
中国抗癌协会血液肿瘤专业委员会
中华医学会血液学分会白血病淋巴瘤学组
中国临床肿瘤学会抗淋巴瘤联盟
邱录贵
李建勇
石远凯
Hematology Oncology Committee of China Anti-Cancer Association;Leukemia &Lymphoma Group;Chinese Union of Lymphoma Research;Qiu Lugui;Li Jianyong;Shi Yuankai(Department of Lymphoma,Institute of Hematology and Blood Disease Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Tianjin 300020,China;Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing 211100,China;Department of Medical Oneology,National Cancer Center/National Clinical Research Center for Caneer/Caneer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2018年第12期927-934,共8页
Chinese Journal of Oncology
基金
十二五国家科技支撑计划项目(2014BAI09B12).
关键词
淋巴瘤
造血干细胞移植
中国专家共识
Lymphoma
Hematopoietie stem cell transplantation
Chinese expert consensus
